RE: Synairgen’s investment case in a nutshell.4 May 2024 14:31
So Dr.Know-It-All, explain the hiring of a new CMO in November, along with a new CFO in November, along with a new Financial Controller and at least 2 clinical trial operatives? Explain the comms black out since that period? Explain the UKHSA taking it upon themselves (allegedly without active company input) to showcase at a global and sold out ID conference, the (scientifically proven) viral agnostic capabilities of SNG001, amongst a sea of others they could have chosen. Then explain that in the context of a real and escalating global threat of H5N1 human-2-human tranmission, where BPs are facing a dearth of available anti-viral therapeutics to deal with any future pandemic scenario, never mind 'normal' pandemic planning. After that, feel free to lecture me and others on why one should have no faith in the company's prospects. I think you are pedalling BS, and I'm not in the market for that.
Do you think you'll get your 15p back ?